|
Volumn 173, Issue 3, 1996, Pages 750-753
|
Treatment of Mycobacterium avium complex infection: Does the beige mouse model predict therapeutic outcome in humans?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CLOFAZIMINE;
ETHAMBUTOL;
RIFAMPICIN;
TUBERCULOSTATIC AGENT;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANIMAL TISSUE;
ARTICLE;
BACTERIOSTASIS;
CLINICAL ARTICLE;
CLINICAL TRIAL;
COLONY FORMING UNIT;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOSE RESPONSE;
DRUG EFFICACY;
DRUG RESPONSE;
HUMAN;
HUMAN TISSUE;
LIVER;
MOUSE;
MYCOBACTERIOSIS;
MYCOBACTERIUM INTRACELLULARE AVIUM;
NONHUMAN;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
SPLEEN;
TREATMENT OUTCOME;
AIDS RELATED COMPLEX;
ANIMAL;
ATYPICAL MYCOBACTERIOSIS;
BACTERIAL COUNT;
COMPARATIVE STUDY;
DISEASE MODEL;
MICROBIOLOGY;
SPECIES DIFFERENCE;
AIDS-RELATED OPPORTUNISTIC INFECTIONS;
ANIMALS;
ANTITUBERCULAR AGENTS;
CLOFAZIMINE;
COLONY COUNT, MICROBIAL;
DISEASE MODELS, ANIMAL;
ETHAMBUTOL;
HUMANS;
LIVER;
MICE;
MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION;
RIFAMPIN;
SPECIES SPECIFICITY;
SPLEEN;
|
EID: 0029664875
PISSN: 00221899
EISSN: None
Source Type: Journal
DOI: 10.1093/infdis/173.3.750 Document Type: Article |
Times cited : (7)
|
References (5)
|